BridgeBio Oncology Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 84

Employees

  • Stock Symbol
  • BBOT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.98
  • (As of Monday Closing)

BridgeBio Oncology Therapeutics General Information

Description

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Contact Information

Website
www.bbotx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 256 East, Grand Avenue
  • Suite 104
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 256 East, Grand Avenue
  • Suite 104
  • South San Francisco, CA 94080
  • United States

BridgeBio Oncology Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BridgeBio Oncology Therapeutics Stock Performance

As of 16-Nov-2026, BridgeBio Oncology Therapeutics’s stock price is $1.98. Its current market cap is $158M with 80.3M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.98 $2.13 $1.97 - $14.87 $158M 80.3M 623K -$2.15

BridgeBio Oncology Therapeutics Financials Summary

As of 30-Sep-2026, BridgeBio Oncology Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 105,517 536,060
Revenue 0 0 0 0
EBITDA (185,951) (144,777) (80,444) (64,679)
Net Income (171,533) (134,044) (74,275) (64,699)
Total Assets 346,224 448,381 164,301 5,942
Total Debt 2,381 2,766 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BridgeBio Oncology Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BridgeBio Oncology Therapeutics‘s full profile, request access.

Request a free trial

BridgeBio Oncology Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BridgeBio Oncology Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BridgeBio Oncology Therapeutics‘s full profile, request access.

Request a free trial

BridgeBio Oncology Therapeutics Acquisitions (1)

BridgeBio Oncology Therapeutics’s most recent deal was a Merger/Acquisition with Helix Acquisition II. The deal was made on 11-Aug-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Helix Acquisition II 11-Aug-2025 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view BridgeBio Oncology Therapeutics’s complete acquisitions history, request access »

BridgeBio Oncology Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view BridgeBio Oncology Therapeutics’s complete esg history, request access »

BridgeBio Oncology Therapeutics FAQs

  • When was BridgeBio Oncology Therapeutics founded?

    BridgeBio Oncology Therapeutics was founded in 2016.

  • Where is BridgeBio Oncology Therapeutics headquartered?

    BridgeBio Oncology Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of BridgeBio Oncology Therapeutics?

    BridgeBio Oncology Therapeutics has 84 total employees.

  • What industry is BridgeBio Oncology Therapeutics in?

    BridgeBio Oncology Therapeutics’s primary industry is Drug Discovery.

  • Is BridgeBio Oncology Therapeutics a private or public company?

    BridgeBio Oncology Therapeutics is a Public company.

  • What is BridgeBio Oncology Therapeutics’s stock symbol?

    The ticker symbol for BridgeBio Oncology Therapeutics is BBOT.

  • What is the current stock price of BridgeBio Oncology Therapeutics?

    As of 16-Nov-2026 the stock price of BridgeBio Oncology Therapeutics is $1.98.

  • What is the current market cap of BridgeBio Oncology Therapeutics?

    The current market capitalization of BridgeBio Oncology Therapeutics is $158M.

  • What is BridgeBio Oncology Therapeutics’s annual earnings per share (EPS)?

    BridgeBio Oncology Therapeutics’s EPS for 12 months was -$2.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process